ESPR Q2 2025 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$82M+11.6% YoY

Gross Profit

$54M65.4% margin

Operating Income

$7M8.6% margin

Net Income

-$13M-15.4% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+26.8%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$347M

Total Liabilities

$781M

Stockholders' Equity

-$434M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$74M	+11.6%
Gross Profit	$54M	$58M	-7.5%
Operating Income	$7M	$3M	+175.1%
Net Income	-$13M	-$62M	+79.5%

Revenue Segments

Collaboration Revenue

$42M51%

Product

$40M49%